What's Happening?
A recent genetic study has identified the gene for growth differentiation factor 15 (GDF15) as a significant cause of hyperemesis gravidarum (HG), a severe form of nausea and vomiting during pregnancy. The study, published in Nature Genetics, is the largest
of its kind and highlights GDF15 as a primary genetic risk factor for HG. The research also discovered six additional genes associated with the condition, including one linked to glucagon-like peptide-1 (GPL-1), a hormone involved in insulin regulation and appetite. This gene is also a known risk factor for type 2 diabetes. The findings could lead to new treatment options for HG, which currently lacks FDA-approved treatments. The study involved data from over 11,000 individuals with HG and more than 420,000 without the condition, primarily of European descent, but also included diverse populations.
Why It's Important?
The identification of GDF15 as a key genetic factor in HG provides a clearer understanding of the condition, which affects up to 10.8% of pregnant individuals with severe symptoms. This discovery opens avenues for developing targeted therapies and improving diagnostic and preventive measures for HG. Additionally, the link between GDF15 and type 2 diabetes suggests a potential overlap in the genetic pathways of these conditions, which could influence future research and treatment strategies. The study's findings emphasize the complexity of HG and its connection to broader metabolic processes, potentially impacting public health approaches to managing pregnancy-related complications and diabetes.
What's Next?
Researchers plan to conduct a clinical trial involving metformin, a diabetes medication that increases GDF15, to test its effectiveness in reducing HG symptoms. The trial will involve participants with a history of HG who are planning future pregnancies. This research could lead to new preventive treatments for HG. Meanwhile, the Hyperemesis Education and Research Foundation continues to support research and advocacy efforts. The study's findings may also prompt further investigation into the genetic links between HG and other metabolic disorders, potentially leading to broader applications in medical research and treatment.
